Therefore, blocking ox-LDL-induced endothelial dysfunction mediated by the LOX-1/NOX-4/ NF-κB pathway may serve as a therapeutic strategy for the treatment of ASCVD. The gene discussed is NFKB1; the disease is endothelial dysfunction.